Xero Swings to 1st Half Profit, Maintains Fiscal Year Costs Forecast
By Stuart Condie
SYDNEY--Xero swung to a first-half profit and maintained its full-year expense target after the cloud-accounting software provider lifted revenue by 21%.
The New Zealand-based company on Thursday reported a net profit of 54.1 million New Zealand dollars (US$32.1 million) for the six months through September, compared with a NZ$16.1 million loss a year earlier.
Revenue rose to NZ$799.5 million, from NZ$658.5 million. Earnings before interest, tax, depreciation and amortization rose 90% to NZ$206.1 million as Xero reduced its operating-expenses-to-operating-revenue ratio to 79.1% from 83.9% a year earlier.
Xero still expects that to fall to about 75% across the whole of fiscal 2024 due to changes that include a previous 15% reduction in workforce.
Xero did not declare a dividend. The average analyst forecast had been for a net profit of NZ$63 million and revenue of NZ$804 million, according to data compiled by analysts.
Write to Stuart Condie at stuart.condie@wsj.com
(END) Dow Jones Newswires
November 08, 2023 17:09 ET (22:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track